The fetoacinar pancreatic protein (FAP), characterized by the mAb J28, is an oncofetal form of bile salt dependent lipase (BSDL), the expression of which is related to pancreatic differentiation and neoplastic processes. Because the J28 epitope, recognized by mAb J28, is suggested to be dependent upon carbohydrates, we have attempted to gain information about the structure of this epitope. Indeed, treatment of FAP with sodium periodate abolished the reactivity of the protein to mAb J28, which demonstrates the implication of oligosaccharides in the structure of the J28 epitope. FAP offers both 0-Iinked and iV-Iinked carbohydrate structures, of which, as we have determined, one is involved. Peptides obtained after cyanogen bromide cleavage were desialylated then separated by affinity chromatography on an immobilized peanut agglutinin agarose column. The peptide retained on this column carried out the reactivity with the mAb J28. Although some differences in amino acid analysis were observed, the N-terminal sequence of this peptide correlates with that of the Ctenninal part of the enzyme. Carbohydrate analysis of the peptide bearing the J28 epitope revealed fucose, galactose, jV-acetylgalactosamine, A'-acetylglucosaraine, and Nacetylneuraminic add. The competition observed between mAb J28 and Ulex europaeus I lectin for binding to the J28 epitope suggested that fucose residue a (1-2) linked to a galactose residue was implicated in the structure of the J28 epitope. Alternatively, the loss of the mAb J28 reactivity upon treatment of FAP either with bovine kidney or bovine epididymis fucosidase was observed indicating that fucose residues linked at the a (1-2) and a (1-6) positions may be involved in the establishment of the structure of the J28 epitope. These observations suggest that mAb J28 recognized a particular fucosylated 0-linked oligosaccharide structure located at the mucin-like extended C-terminal part of FAP.
Introduction
The bile salt-dependent lipase (BSDL) secreted by the pancreas plays an essential role in cholesterol and lipid-soluble vitamin absorption (Rudd and Brockman, 1984; Erlanson-Albertson, 1986; Wang and Hartsuck, 1993) . BSDL is found in all pancreatic secretions examined up to now, from fishes to human (Blackberg et al, 1981; Freed et al, 1986; GjeUesvick et al., 1992) . All sequenced BSDL have a site for TV-linked glycosylation on Asn-187 (Reue et al., 1991) close to the Ser-194 involved in substrate catalysis (DiPersio et al., 1990) . This TV-linked glycosylation was shown to be cotranslational and essential for the secretion and expression of a fully active enzyme by pancreatic cells . Interestingly, the structure of this TV-linked glycosylation depends upon the physiopathological statute of the pancreas (Mas et al, 1993b) . Serum concentration of BSDL is enhanced in pancreatitis (Blind et al, 1987; Lombardo et al., 1993) whereas it is diminished in cancer (Lombardo et al, 1993) . The size of BSDL varies by species due to a variable amount of C-terminal tandem repeated sequences. The human enzyme possesses 16 repeated sequences (Reue et al, 1991) and is the largest (100 kDa). These repeated sequences, rich in proline, glutamic acid, serine, and threonine (Reue et al, 1991) , are sites for 0-linked glycosylation (Mas et al, 1993b; Sugo et al., 1993; Wang et al, 1995) . The function of this C-terminal domain has remained unknown but it may dictate intracellular transport of BSDL (DiPersio et al., 1994) . In part, it could be responsible for the interaction of BSDL with a membrane folding complex including a 94 kDa protein immunologically related to the glucose regulated protein of 94 kDa (i.e., Grp94). The release of BSDL from intracellular membranes occurs when terminal sugars, such as fucose, are added to glycan; consequently, the Grp94-related protein of 94 kDa was assumed to assist the adequate sorting of BSDL (Bruneau and Lombardo, 1995; Bruneau et al, 1995) .
Fetoacinar pancreatic protein (FAP) is a member of the oncodevelopment-associated pancreatic antigens. It was first identified using polyclonal antisera in the Syrian golden hamster (Benedi et al, 1984; Escribano et al, 1985; Eriguchi et al, 1987) as well as in human pancreas where FAP was further characterized with a murine monoclonal antibody, mAb J28, which recognized a structure referred to as the J28 epitope (Escribano and Albers, 1986) . The earliest expression of FAP was seen in undifferentiated mesenchymal cells and in nascent acini at the beginning of the pancreatic morphological differentiation. However, the protein has not been detected in other fetal tissues (Albers et al., 1987) . Maximal synthesis occurs at the time of intense acinar cell proliferation (15-25 weeks of gestation) and declines progressively thereafter (Albers et al., 1987) . Although FAP is not expressed in any normal adult tissues, it has been detected in the adult pancreas where the protein is poorly expressed. Serum FAP concentration, detected with mAb J28, is enhanced in pancreatic pathologies, especially adenocarcinomas (Fujii et al, 1987) . FAP is also found in amniotic fluids and in relatively high concentrations in pathological pancreatic juices (Carrd-E.Mas el al Llopis and Escribano, 1986) . We have shown that FAP is an oncofetal related variant of BSDL (Mas et al, 1993a) , which can be separated from BSDL by immunoaffinity on immobilized mAb J28. The two subpopulations have identical Nterminal sequences but some differences can be detected in their amino acid compositions. FAP (that is, the mAb J28 reactive BSDL subpopulation) is active on BSDL specific substrates, although its specific activity is lower than that of BSDL (Mas et al, 1993a) . However, FAP and BSDL have different carbohydrate compositions. TV-Linked oligosaccharide structures of BSDL are of the complex type (Sugo et al., 1993) whereas that of FAP are correlated with high-mannose or hybrid type structures (Mas et al, 1993a) . The amount of Olinked glycans is greatly decreased in FAP where fucose residues are the most represented sugar (Mas et al, 1993a) . These results indicated that FAP was probably a glyco-isoform of BSDL. Therefore, it has been suggested that the J28 epitope is a carbohydrate-dependent structure (Escribano and Imperial, 1989) . Because of the application of BSDL (Lombardo et al, 1993) and FAP (Fujii et al, 1987) assays in serum for the early diagnosis of pancreatic cancer, we attempted in the present study, to gain further information about the structure of the J28 epitope.
Results

Implication of oligosaccharid.es in the structure of the J28 oncofetal epitope
To demonstrate the implication of oligosaccharides in the J28 epitope structure, decreasing quantities of FAP (from 1 u,g to 0 n-g) were dotted on a nitrocellulose membrane. The reactivity of mAb J28 with dotted FAP was then tested in the presence of increasing quantities (from 0 to 10 (xg/ml) of native FAP or FAP digested with pronase as soluble competitive material. As expected, the reactivity of dotted FAP with mAb J28 decreased as the concentration of competitive material, such as native FAP, increased (Figure 1 ). Indeed, identical results were obtained when pronase-digested FAP was used as competitive material (Figure 1 ). Considering that FAP pronase digestion broke up the protein core of FAP (as verified by SDS-PAGE) leaving sugar structures unaffected, this suggested that oligosaccharide structures were likely involved in the J28 epitope.
In another set of experiments, oligosaccharide structures of FAP were cleaved by periodate sugar oxidation. As shown in Figure 2 , periodate abolished the reactivity of mAb J28 with FAP. Taken together, diese data demonstrated the implication of oligosaccharide structures in the J28 oncofetal epitope.
Involvement of the O-glycosylation of FAP in the structure of the J28 epitope
Because FAP carries out both O-and N-glycans, we have determined which glycan the J28 epitope is associated with. For this purpose, FAP was first labeled with [ 3 H] diisopropylfluorophosphate (DFP), hydrolyzed with cyanogen bromide and freeze-dried. Peptides were separated by filtration on a Sephadex G25 superfine column (1 x 110 cm) eluted with a 0.1 M Tris-HCl buffer, containing 0.5 M guanidine-chloride at pH 8.5. Data indicated that the peptide reactive with mAb J28 was clearly dissociated from the radiolabeled one (Figure 3 ). Since the radioactivity tagged the peptide which carried A'-linked glycans, we concluded that the J28 epitope is not associated with the Af-linked carbohydrate structure present on FAP. Con-300 0 2 4 6 8 10 Competitive material (|xg/ml) Fig. 1 . Competitive dot-blot. Native FAP after serial 2-fold dilutions was immobilized on a nitrocellulose membrane. The immunodetection was performed using mAb J28 as the primary antibody in the presence of increasing concentrations of competitive material: (circle) native FAP; (triangle) pronase-treated FAP. The amount of mAb J28 reactive material (U/ml) was determined as described by Escribano and Imperial (1989) . Data are the average of two independent experiments. sequently, the protein was treated with Endoglycosidase F or N-Glycosidase F and assayed by enzyme-linked inununosorbent. Neither endoglycosidase F, which cleaves the jV-glycan linkage of glycoprotein leaving free Asn, nor /v'-Glycosidase F, which cleaves /V-linked oligosaccharide within the chitobiose core of the carbohydrate side chain, had definite effect on the mAb J28 reactivity (not shown). All these data suggested that the Af-linked oligosaccharide structure of FAP is probably not involved in the structure recognized by mAb J28. Therefore, we examined the possible implication of O-linked structures. FAP (ng/ml) Peptides obtained as above were desialylated then separated by affinity chromatography on an agarose-inunobilized peanut agglutinin (PNA) column (Figure 4 ). Results indicated that only 17% of radioactive material associated with mAb J28 was eluted with the elution buffer while 75% was recovered in fractions eluted with lactose. This data suggested that the J28 epitope may be associated with the 0-linked glycosylation of FAP. Peptides eluted with lactose and bearing the J28 epitope were separated on SDS-PAGE and electrotransferred onto a 3 H]DFP-labeled FAP were desialylated in PBS, 10 mM EDTA with 100 mil of neuraminidase (37°C, overnight). Desialylated peptides (300 u.g) in PBS, 0.5% Triton X-100, 1 mM CaCl 2 and 1 mM MgCl 2 , were loaded onto the agarose-immobilized PNA lectin column and incubated 5 h under roll-agitation. The gel was washed successively with the loading buffer until no radioactivity was detected, then with PBS, 0.1% Triton X-100. The bound material was then eluted with PBS, 0.1% Triton X-100, 0.3 M lactose. The whole procedure was performed at 4°C. Fractions (1 ml) were collected; radioactivity (filled circle) was determined and the J28 epitope reactivity (open circle)was detected by enzyme-linked immunosorbent as described in Materials and methods.
nitrocellulose membrane. As shown in Figure 5 , the reactivity with mAb J28 was associated with peptides of approximately 50-60 kDa as was the reactivity of PNA and UEA-1. All these data demonstrate that the O-glycosylation of FAP is likely involved in the structure of the J28 epitope. As deduced from the amino acid sequence of human BSDL (Reue et al., 1991) , no peptide of 50-60 kDa can be generated by cyanogen bromide cleavage. Subsequent treatment of this peptide with trypsin has no effect on its electrophoretic migration. Therefore, the Mr of the mAb J28 reactive peptide obtained on SDS-PAGE suggested an aberrant electrophoretic migration characteristic of a highly glycosylated peptide. We have determined the N-terminal sequence of this peptide (Table I) and found identical alignment with the BSDL sequence starting with Lys 511. As expected, this sequence corresponds with that of the C-terminal peptide of BSDL to which is associated the Oglycosylation (Mas et al, 1993b; Sugo et al, 1993; Wang et al., 1995) . Amino acid analyses of the peptide showed a high amount of Glx, Gly, Ser, Thr, and Pro residues which are different from those of the C-terminal fragment of BSDL (Table H) (Reue et al, 1991) .
The carbohydrate analysis of this peptide was performed and the molar ratios of the different monosaccharides are given in Table HI . With regard to the composition, it may be deduced that the carbohydrate moiety consists exclusively of O-linked glycans. According to the ratio fucose/N-acetylgalactosamine (0.7:1), it may be assumed that most of the glycans are fucosylated. It should be mentioned that the glycopeptide was partially desialylated after the neuraminidase treatment as indicated by the presence of remaining sialic acid residues. The total carbohydrate content of the glycopeptide was estimated at 17%.
Therefore, it is suggested that the peptide which carries the J28 epitope contains an O-linked minimal structures) comprised of a stoichiometric amount of galactose and galactosamine, which are likely fucosylated and sialylated.
Involvement offucose residues in the structure of the J28 epitope
This result obtained above suggested that fucose residue(s) were probably involved in the J28 epitope structure. We first assayed whether UEA-I lectin which recognizes a 1-2 fucose 'Deduced from C-terminal part of the cDNA sequence (Reue et al, 1991) .
residue linked to galactose residue (Pereira et al., 1978) could compete for the epitope recognition by mAb J28. As shown in Figure 6 , the binding of mAb J28 to FAP was largely decreased after binding with this lectin. Interestingly, when PNA, which reacts with Gaip(l-3)GalNAca(l-3)-0-linked oligosaccharides, was used instead of UEA-I, independent of a prior treatment of FAP with neuraminidase, no binding impairment was observed (Figure 6 ). This data demonstrated that PNA and mAb J28 may bind independently to different O-linked structures while the effect of the UEA-I lectin on mAb J28 reactivity suggests that a fucose residue a (1-2) linked to a galactose residue is implicated in the structure of the J28 epitope. Furthermore, the involvement of sialyl residues in the J28 epitope structure can be ruled out.
To ascertain the implication of fucose residues in the J28 epitope structure, FAP was treated with fucosidase from bovine kidney which hydrolyzes terminal a (1-2), a (1-3) and a {\-4) linked fucose residues. FAP thus treated was subsequently unable to react with mAb J28 (Figure 7) . Fucosidase from bovine epididymis, which preferably cleaves a (1-6) linked fucose, was also used in a parallel experiment. As shown in Figure 7 , treatment of FAP with the former enzyme also abolished mAb J28 reactivity towards FAP. All together, these data indicated that fucose residues, possibly linked in a (1-2) and a (1-6) position of the sugar sequence, may be involved in the structure of the J28 epitope. 
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"Theoretical indicates the amino acid composition corresponding at the C-terminal peptide deduced from the cDNA sequence from nucleotide A1610 (Lys 511) (Reue et aL, 1991) . ""Average of two independent determinations. n.d., Not determined. Residues that clearly differ in amount are underlined. The molar ratio is corrected for one N-acetylgalactosamine residue. 'Theoretical peptide core molecular weight is 21,000.
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Relationship between the J28 epitope and blood-group related carbohydrate antigens
Specific antibody reactivity for blood group antigens (as mentioned in Materials and methods) with FAP was determined by dot-blot dilution. The results showed that FAP was not reactive with any of these specific antibodies including Lewis type group (type I and type II antigenic determinants). The reactivity was also negative with the type III (9-glycosylated precursor T antigen and the monosialylated Tn antigen. Only a polyclonal antiserum directed against the Le x antigenic structure was reactive with FAP. In addition, this antiserum was also reactive with BSDL devoid of mAb J28 reactivity (not shown). This indicates that Lewis type structures may be present on BSDL. Competitive ELISA performed in the presence of Htype 1, H-type 2, and H-type 3 carbohydrate structures as competitors (up to 1000-fold molar excess versus J28 epitope) also indicated that the J28 epitope was related to neither of these structures. Obviously, the J28 epitope had no relationship with any of these structures, and one can suggest that the structure recognized by mAb J28 should be original.
Discussion
The earliest expression of FAP is seen in undifferentiated mesenchymal cells and in nascent acini at the beginning of the pancreatic morphological differentiation. Maximal synthesis occurs at the time of intense acinar cell proliferation, declines progressively thereafter (Albers et al., 1987) , and reaches, in the adult, levels far lower than those observed in the fetus (Albers and Escribano, 1986; Albers et al., 1987) . FAP was re-expressed in pancreatic adenocarcinoma for which it represents an early marker (Fujii et al., 1987) . Drastic treatment of FAP with a cocktail of glycosidases including neuraminidase, hexosaminidase and O-glycanase abolished the reactivity of mAb J28 suggesting that the J28 epitope recognized by this monoclonal antibody was carbohydrate-dependent (Escribano and Imperial, 1989) . Carbohydrate antigens diminish or disappear depending on the stage of development and sometimes become restricted to certain cell types in adult tissues, where they can be re-expressed during neoplastic processes. These jumping antigens can either be due to additional or incorrect glycosylations, incomplete biosynthesis or glycosidase actions. Data presented in this study confirm that the J28 epitope present on FAP involves a carbohydrate structure. However, because FAP had <9-linked and TV-linked carbohydrate structures, the first question was to determine which of the O-or TV-linked structures was involved in the J28 epitope.
As above mentioned, the structure of the FAP //-linked glycan differed from that of BSDL. In addition, we showed that the TV-linked structure of BSDL varied with pancreatic pathologies (Mas etal., 1993b) . Therefore, any structural modification may generate the J28 epitope. When the TV-linked glycan was tagged by labeling the proximal serine residue involved in the catalytic site by [ H]DFP, we were able to dissociate the mAb J28 reactive peptide from that which carried out TV-linked glycosylation. Likewise, treatments with TV-endoglycosidase did not lead to the loss of mAb J28 reactivity, demonstrating that TV-linked glycosylation of this protein is not involved in the structure of the oncofetal J28 epitope. Since data (Escribano and Imperial, 1989 , and this study) indicated that an oligosaccharide structure was involved in the J28 epitope structure, an CMinked glycan(s) might be a candidate. The first piece of evidence was the parallel reactivity of PNA and mAb J28. This parallelism may be demonstrated either by Western blot or by immobilized-PNA affinity column of peptides obtained after cyanogen bromide cleavage of FAP. Added evidence was given by the amino acid composition of mAb J28 and PNA reactive material which is rich in Pro, Gly, Asp, Glx, Ala, Ser, and Thr residues. The latter two may be involved in the 0-linkage with the carbohydrate structure. These residues were mainly located on C-terminal tandem repeated mucin-like sequences of the normal variant of FAP, e.g., BSDL (Reue et al., 1991) . The amino acid composition of FAP differs from that of BSDL in amino acids involved in the sequence of these tandem repeats (Mas et al., 1993a) . Therefore, the difference in amino acid composition observed between the mAb J28 active peptide and the theoretical C-terminal peptide likely reflects a polymorphism resulting from modifications either in amount and/or in sequence of tandem repeats. These tandem sequences of BSDL were shown to cany 12 to 14 O-linked Gal-GalNAc structures which are shrouded by capping sialyl residues bound to terminal galactose residues (Mas et al., 1993b) . The increased reactivity of PNA which recognizes Gal (31-3 GalNAc structures with the fucosidase-treated BSDL (Mas et al, 1993b) implies that some (9-Unked oligosaccharide structures are fucosylated. Compare to BSDL (Mas et al., 1993a) , the amount of O-linked structures decreased in FAP whereas the Fuc/NeuAc ratio increased, which suggested that the J28 epitope may be fucosylated even though it is not related to any ABH blood group or Lewis related structures as demonstrated here. The quenching of mAb J28 reactivity with FAP by the UEA-I lectin is a strong evidence for the involvement of an a (1-2) linked fucose residue in the J28 epitope structure. Kidney and epididymis fucosidases abolished the reaction between the antigen and the antibody. Because these enzymes cleave preferentially o (1-2) and a (1-6) linked fucose residues, respectively, one may suggest that a (1-2) and a (1-6) linked fucose residues are likely involved in the structure of the J28 epitope. Retention of antigenicity of FAP following heat treatment in the presence of a detergent (Triton X-100, SDS) or a reducing agent ((3-mercaptoethanol) and the observed competition with the pronase-treated FAP, did not favor a partial protein epitope. Considered together, all these results indicated that the J28 epitope accommodates a polyfucosylated structure different from that of Le b or Le* epitope structures. Treatment of FAP with neuraminidase did not prevent mAb J28 binding and demonstrated that sialic acid residues might not be involved in the oncofetal J28 epitope structure. As a consequence, the J28 epitope is not considered related to sialylated antigenic structures such as those of CA19-9 or CA-50 antigens which are frequently detected at elevated levels in malignant pancreatic disease (Hanisch et al., 1984; Kawa et al., 1991) . Moreover, CA19-9 is not specific for pancreatic cancer because it is also associated with colorectal and gastric cancers (Magnani et al, 1983) . Conversely, the J28 epitope which is borne by a pancreatic protein, could be the first specific marker of pancreatic cancer. Works are currently in progress to determine the sugar sequence involved in the structure of the J28 oncofetal epitope.
Materials and methods
Materials
Human pancreatic juice was collected by carheterization of the main pancreatic duct on patients after gastric or colonic surgery. Only samples devoid of free proteolytic activity as determined on W-acetyl-L-tyrosine ethyl ester as sub-E.Mas et al strate (chymotrypsic activity), were used. Fucosidases from bovine kidney and epididymis, alkaline phosphatase-conjugated anti-mouse goat IgG and IgM, alkaline-phosphatase-conjugaled-antibiotin-antibodies fatty acid-free serum albumin, Tween 20, nitroblue tetrazolium, 5-bromo-4-chloro-3-indoyl phosphate, agarose immobilized-PNA, biotin labeled PNA and UEA-I and cyanogen bromide were obtained from Sigma (St. Louis, MO). Nitrocellulose membranes were from Schleicher and Schuell (DasseL Germany). Clostridium perfringens neuraminidase, pronase, W-Glycosidase F and Endoglycosidase F came from Boehringer (Mannheim, Germany). Polyvinylpyrolidone K40 (PVP 40) and Coomassie blue R250 were from Fluka (Buchs, Switzerland). Paranitrophenyl phosphate was from Merck (Darmstadt, Germany). [
3 H] Diisopropylfluorophosphate (1.628 10" Bq/mmol) was from NEN (Les Ulis, France). Lacto-A'-fucopentaose I : H-type 1 (Fucal-2GalBl-3GlcNAcBl-3GalfH-4Glc) and 2'-Fucosyllactose: H-type 2 (Fuca\-2Gal$\-4G\c) were obtained from Oxford Glycosystems (Abingdon, UK) and H-type 3-PAA (Fucal2GalBl-3GalNAc-O(CH 2 ) n -) was from Syntesome Ltd. (Moscow, Russian Federation).
Antibodies
The munne monoclonal antibody (mAb) J28 directed against FAP was obtained as described previously (Albers et al, 1987; Fujii et al, 1987) . A polyclonal antiserum against BSDL was raised in rabbit (Lombardo et al., 1978) . Polyclonal immunoglobulins were then purified on protein A-Sepharose and referred to as pAb L64. Anti Le b (clone 2-25 LE), anti A-type I (clone 3-3A), anti Le* (clone 7-LE), anti Le* (clone 12-4 LE), anti-H type 2 (clone 19-0-LE), and anti msLe* (clone 121-SLE) were generously donated by Dr. Jacques Bara, Hospital St Antoine, Paris (France). Anti Le* (clone SH 1), anti ds Le' (clone FH 7, , anti ms TN (clone TKH1), anti A (clone HH5), and anti T (clone HH8) were a gift from Dr. Else K. Philipsen Kas, Sankt Elisabeth Hospital, Kobenhaum (Denmark). Anti B-type I (clone 95.3) and anti H-type I (clone HMS2 110A1A4) were obtained from Sanofi Diagnostic Pasteur, Mame-la-Coquette (France).
ary antibodies conjugated to alkaline phosphatase were used to develop the reaction.
Enzyme-linked immunosorbent assay (EL1SA)
Nunc Maxisorb F96 certified immunoplales were coated with 100 uJ/well of a solution of pAb L64 diluted to a concentration of 10 jig/ml in 0.1 M carbonate buffer, pH 9.5. The plates covered with adhesive and protected with an aluminum sheet, were activated for at least 12 h at 4°C. Wells were washed three times with 300 ui 10 mM sodium phosphate buffer, pH 7.4, containing 0.05% Tween 20 (PBS/Tween). Wells were saturated with 1% BSA (200 uJ/well) in PBS/Tween (30 min, 37°C) and washed three times with PBS/Tween. The samples and control solution (diluted from 5 M.g/ml to 0.005 p.g/ml) were then added to 100 u.1 of PBS/Tween. Plates were incubated 2 h at 37°C and then washed as above. One hundred microliters of a PBS/Tween solution of mAb J28 (-5 u-g/ml) were added with or without competitive structures, incubated 2 h at 37°C, and washed as described above. Antibodies against alkaline phosphatase-conjugated mouse IgG (5 u.g/m] in PBS/Tween) were added to each well and incubated 30 min at 37°C. Finally, after extensive washing, 100 |xl of p-nitrophenylphosphate (1 mg/ml in 0.2 M Tris-HCl buffer, pH 8.2 containing CaCl 2 and MgCl 2 lmM each) was added and incubated 1 h at 37°C. Plates were then read with a MR 5000 microplate spectrophotometer (Dynatech, BiUingshurst, UK) at 405 nm. Controls were performed using serial dilutions of purified FAP.
Penodate treatment
To degrade ohgosaccharide structures, FAP was assayed after a mild periodate oxidation procedure. For this purpose FAP was treated with 50 mM or 100 mM sodium periodate in 50 mM sodium acetate buffer, pH 5, for 1 h at room temperature in the dark while the control series was treated with buffer only. After saturation with 0.2 M glycine, FAP was diluted (from 0.5 u.g to 0.0005 u-g in 100 u,l) in PBS/Tween and assayed by sandwich-linked immunosorbent.
Protein purification
BSDL was purified from human pancreatic juices by the conventional physicochemical method (Lombardo et aL, 1978) . FAP was isolated from preparation of BSDL as reported previously using agarose-immobilized mAb J28 (Mas et al, 1993a) .
Polyacrylamide gel electrophoresis and Western blot
Gel electrophoresis (SDS-PAGE) were performed in slab gel in 10% polyacrylamide and 0.1% sodium dodecyl sulfate according to Laemmli (Laemmli, 1970 ) using a Bio-Rad mini-protean n apparatus. Proteins were either stained by Coomassie blue R250, or electrophoretically transferred to nitrocellulose membrane (Bumette, 1981) . Immunodetection was done using the monoclonal antibody mAb J28 as primary antibody. Nitrocellulose membranes were then incubated in a buffered BSA solution containing alkaline phosphataseconjugated anti-mouse goat IgG. Development was performed with a mixture of nitroblue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate in 0.1 M Tris-HCl buffer, pH 9.5 (0.1 M NaCl and 1 mM MgCy for 10 min.
Lectin affinity blottings
Lectm affinity blottings were performed after electrophoretic transfer. Detection and development were performed as previously described (Mas et al, 1993b) .
Semi-quantitative dot-blot
Serial 2-fold dilutions of FAP were dotted using a Bio-Dot apparatus (Bio-Rad, Hercules, CA) on nitrocellulose membrane, air-dried for 30 min, and blocked as described for Western blot. Immunodetection was done using mAb J28 as the primary antibody in the presence of an increasing amount of native or pronase-digested FAP. Under these conditions, the soluble material should compete with the immobilized one for mAb J28 recognition. Consequently, the number of positive dilutions would decrease with an increasing amount of competitive material. Development was performed as described above for Western blots. The amount of J28 epitope was calculated by reference to the last dilution in a series using the following equation: J28 (U/ml) = 2 <Q~" , where n is the number of positive dilutions (Escribano and Imperial, 1989) . Semi-quantitative dot-blots were also performed using monoclonal antibodies specific for blood-group related antigens (see Abbreviations). Specific second-
Enzymatic modifications of FAP
Digestions with N-glycosidase F (PNGase) or endoglycosidase F2 (Endo-F) were carried out as follows: 5-10 u.g of FAP (1 mg/ml) was boiled for 15 s in 0.5% SDS, and then PBS, pH 7.4, buffer with 50 mM EDTA, 10 mM N 3 Na, and 0.5% Triton X-100 was added. The mixture was again boiled for 15 s. Half of the mixture was used as control and the second half was incubated overnight at 37°C with 0.70 U of PNGase. With Endo-F (0.2 mU) the incubation was performed in 200 mM sodium acetate pH 4.5 buffer. The fucosidase (from bovine kidney or bovine epididymis) treatment was performed under the same conditions as those described for PNGase. The buffer used was 20 mM sodium phosphate pH 7.4 widwut NaCl while other constituents were identical. Incubation was completed overnight at 37°C in the presence of 25 mU of fucosidase. When required, material was desialylated in 50 mM sodium acetate buffer, pH 5.0, 2 h at 37°C with neuraminidase (10 mU/ml) and dialyzed before further treatment. The digestion of FAP by pronase (4% by weight) was done after an overnight incubation at 37°C in 5 mM Tris-HCl buffer, pH 7-5, containing 2 mM CaCl 2 . At the end of the incubation period, no trace of native protein could be detected with Coomassie blue after SDS-PAGE.
Masking of the J28 epitope
FAP dilutions were incubated with pAb L64-coated immunoplates. Wells were firstly washed with PBS/Tween. Ulex europaeus I (UEA-I) lectin or peanut agglutinin (PNA) lectin (100 M-g/ml in PBS/Tween, 10 u.g/well) was then added. Incubation with PNA lectin required prior treatment of FAP by neuraminidase and the presence of CaCl 2 and MgCl 2 (1 mM each). Plates were incubated overnight at 4°C, washed, and saturated (2 h, 37°C) with 10 mM fucose for UEA-I or with 20 mM lactose for PNA. After exhaustive washing, mAb J28 was added and the protocol continued as described for the enzymelinked immunosorbent.
Reaction of FAP with [ 3 H]DFP
One milligram of FAP in 10 mM Tris-HCl buffer, pH 7.5, was incubated at 37°C for 30 min in the presence of [ 3 H]DFP (1 p.Ci), and then diluted with unlabeled DFP (0.4 UJDOI) and incubated once again at 37°C for 30 min. The labeled enzyme was applied to a column (1-5 x 20 cm) of Sephadex G25 coarse equilibrated with 10 mM Tris-HCl, 150 mM NaCl, pH 7.4. Fractions were collected and radioactivity and absorbance at 280 nm were monitored. Those containing the radioactive protein were pooled and lyophilized for further treatments.
